
|Videos|August 18, 2021
Impact of metastases location on mCRPC treatment selection
Author(s)Urology Times staff
Advertisement
Jingsong Zhang, MD, PhD is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine, discusses how the site of metastases impacts his approach to treatment selection for patients with metastatic castration-resistant prostate cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










